Richard Goldberg

Richard Goldberg contributed to NSABP C-07, which provided complementary evidence to MOSAIC that oxaliplatin-containing adjuvant therapy improves disease-free survival in stage III colon cancer. His work has informed the evidence base for adjuvant therapy decision-making in both stage II and III colon cancer, including high-risk stage II management. He has led cooperative group research examining molecular predictors of adjuvant benefit in CRC. Goldberg has contributed to gastrointestinal oncology guidelines and educational programs throughout his career.